SCHEMBL3340894

SCHEMBL3340894

CCCCCCCCCCc1ccc2c(=O)c(OCc3ccccc3)c(-c3cc(OC)c(OCc4ccccc4)c(OC)c3)oc2c1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.50
CNR1 P21554 8/20 0.48
CNR2 P34972 8/20 0.48
GPR55 Q9Y2T6 6/20 0.45
BCHE P06276 1/20 0.43
ABCG2 Q9UNQ0 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP3A4 P08684 1/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
HPGD P15428 1/20 0.43
KMT2A Q03164 1/20 0.43
HSD17B10 Q99714 1/20 0.43
GPR18 Q14330 1/20 0.42
ALOX5 P09917 5/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4039498 1.00 PPARG (0.50) PPARGCNR1CNR2GPR55BCHE
SCHEMBL4035989 1.00 PPARG (0.50) PPARGCNR1CNR2GPR55BCHE
SCHEMBL4034678 0.97 PPARG (0.49) PPARGCNR1CNR2GPR55BCHE
SCHEMBL4036191 0.97 PPARG (0.49) PPARGCNR1CNR2GPR55BCHE
SCHEMBL13648968 0.97 PPARG (0.49) PPARGCNR1CNR2GPR55BCHE
SCHEMBL4042000 0.94 PPARG (0.51) PPARGCNR1CNR2GPR55ABCG2
SCHEMBL13654317 0.89 ALOX5 (0.49) CNR1CNR2GPR55ABCG2GPR18
SCHEMBL13654240 0.87 ALOX5 (0.51) ABCG2ALOX5
SCHEMBL13654327 0.87 ALOX5 (0.51) ABCG2ALOX5
SCHEMBL13654297 0.87 ALOX5 (0.51) ABCG2ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100151508-A1 COMPOUNDS THE ROBERT GORDON UNIVERSITY 2010-06-17 US disclosed
US-7601754-B2 Flavonoid compounds as therapeutic antioxidants ANTOXIS LIMITED (GB) 2009-10-13 US disclosed
US-7601754-B2 Flavonoid compounds as therapeutic antioxidants ANTOXIS LIMITED (GB) 2009-10-13 US disclosed
US-7601754-B2 Flavonoid compounds as therapeutic antioxidants ANTOXIS LIMITED (GB) 2009-10-13 US disclosed
EP-2087350-A1 COMPOUNDS The Robert Gordon University (GB) 2009-08-12 EP disclosed
WO-2008062184-A1 COMPOUNDS THE ROBERT GORDON UNIVERSITY (GB) 2008-05-29 WO disclosed
EP-1534698-B1 FLAVONOID COMPOUNDS AS THERAPEUTIC ANTIOXIDANTS ROWETT RES INST (GB) 2007-09-19 EP disclosed
EP-1534698-B1 FLAVONOID COMPOUNDS AS THERAPEUTIC ANTIOXIDANTS ROWETT RES INST (GB) 2007-09-19 EP disclosed
US-20060137207-A1 Flavonoid compounds as therapeutic antioxidants ANTOXIS LIMITED (GB) 2006-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151508-A1 COMPOUNDS NFE2L2, RBBP4, GPX4 PPARG 2562/4885CNR1 3487/4885CNR2 3322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.